CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 182 enrolled
Drug / intervention
BodyPort +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04394754
NCT04394754N/ACompleted

Assessing the Efficacy of Digital Health Technology in the Management of Congestive Heart Failure: An Evaluation of Three Novel Digital Health Products

Yale University·interventional·Posted May 19, 2020·Updated May 18, 2023

In Brief

A clinical study evaluating BodyPort, Noom, and 1 other intervention for Congestive Heart Failure. Completed, enrolled 182 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the efficacy of three novel digital health technologies versus usual care in the management of congestive heart failure, as assessed by a primary outcome of improvement in quality of life, and a variety of secondary outcomes that include metrics measuring patient and provider satisfaction, clinical efficiency, and patient outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsBoehringer Ingelheim, ZS

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMay 19, 2020
Enrollment StartSep 21, 2020
Primary CompletionSep 20, 2021
Study CompletionDec 1, 2021
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.1 years ago

Interventions

BodyPortdevice

Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.

Noomother

Patients will receive a subscription to use Noom, a personalized diet and weight management application.

Conversaother

patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.